Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0UAJZK
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
opelkibart elmanitin
|
|||||
| Synonyms |
opelkibart elmanitin; C200; MGTA-117
Click to Show/Hide
|
|||||
| Organization |
Magenta Therapeutics (Originator);Heidelberg Pharma (Originator) (No Rights)
|
|||||
| Drug Status |
Phase 1/2 (discontinued)
|
|||||
| Drug-to-Antibody Ratio |
2
|
|||||
| Antibody Name |
Opelkibart
|
Antibody Info | ||||
| Antigen Name |
Mast/stem cell growth factor receptor Kit (KIT)
|
Antigen Info | ||||
| Payload Name |
α-amanitin
|
Payload Info | ||||
| Therapeutic Target |
RNA polymerase II
|
Target Info | ||||
| Linker Name |
Undisclosed
|
|||||
| Conjugate Type |
Undisclosed
|
|||||
| Combination Type |
elmanitin
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Acute myeloid leukaemia |
1 Trials
|
||||||||
| Myelodysplastic syndrome |
1 Trials
|